- Life science company Cellmid (CDY) has received Australian and Japanese Patents for its haircare technology, alopecia
- These patents protect the company’s anti-aging and hair loss technology
- Cellmid said granting these patents is an important step and follows grants in Europe and China
- On market close, Cellmid is up 2.27 per cent and is selling shares for 22.5¢ per share
Life science company Cellmid (CDY) has received Australian and Japanese Patent for its haircare technology, alopecia.
The Australian Patent is titled “Method of Treatment of Alopecia with Monoterpenoids” and will expire on December 2034.
The Monoterpenoids Patent protects the part of the technology that distinguishes the évolis therapeutic and anti-aging hair care ranges from other products. This patent expires on December 12, 2034.
“These patents provide protection in two key territories representing major markets for the company’s hair therapy formations,” the company said.
Cellmid said granting these patents is an important step and follows recently received grants in Europe and China.
The patents cover members of a class of small molecules called monoterpenoids, originally derived from botanical extracts.
The method covered by the patent involves the administration of a topical
a formulation, containing a monoterpenoid, to discourage the hair growth cycle protein -fibroblast growth factor 5 (FGF5).
Scientific studies have shown that FGF5 activity in hair follicles is related to the disruption of the hair cycle, leading to withdrawal from the growth or anagen phase and entry into the regressive catagen phase, followed by hair loss.
Cellmid’s évolis products have shown to reduce hair loss and increase the number of growing follicles.
On market close, Cellmid is up 2.27 per cent and is selling shares for 22.5¢ per share.